Zolpidem oral spray - Amherst Pharmaceuticals

Drug Profile

Zolpidem oral spray - Amherst Pharmaceuticals

Alternative Names: Zolpidem tartrate oro-mucosal spray - Amherst; Zolpimist

Latest Information Update: 15 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NovaDel Pharma
  • Developer Amherst Pharmaceuticals; Aytu BioScience
  • Class Acetamides; Hypnosedatives; Imidazoles; Pyridines; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Insomnia
  • No development reported Sleep maintenance insomnia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Sleep-maintenance-insomnia in USA (Transmucosal, Spray)
  • 29 Apr 2016 Biomarkers information updated
  • 22 Sep 2014 Amherst Pharmaceuticals acquires patents, trademarks and license agreements related to zolpidem oral spray
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top